Skip to main content

Client News

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

6th September 2021

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

1st September 2021

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

26th August 2021

HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX 0215

10th August 2021

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

10th August 2021

InflaRx to Present at the BTIG Virtual Biotechnology Conference

6th August 2021

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

5th August 2021

InflaRx Reports Second Quarter 2021 Financial & Operating Results

5th August 2021

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

29th July 2021

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

27th July 2021